SEC Form 4 · accession 0000904454-18-000424
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jesse I Treu
Director
Period of report
Jun 7, 2018
Accepted (ET)
Jun 11, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $8.35 | Jun 7, 2018 | A | 15,526 | A | Jun 7, 2019 | Jun 6, 2028 | Common Stock | 15,526 | 15,526 | D |
| Stock Option (right to buy)F2 | $8.35 | Jun 7, 2018 | A | 1,354 | A | Jun 7, 2019 | Jun 6, 2028 | Common Stock | 1,354 | 1,354 | D |
| Stock Option (right to buy)F3 | $8.35 | Jun 7, 2018 | A | 1,444 | A | Jun 7, 2019 | Jun 6, 2028 | Common Stock | 1,444 | 1,444 | D |
Explanation of responses
- F1The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Board of Directors through such vesting date.
- F2The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Audit Committee of the Board of Directors through such vesting date.
- F3The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as the chairman of the Nominating and Corporate Governance Committee of the Board of Directors through such vesting date.